AI in drug discovery hopes mount

What happened: Johnson & Johnson (JNJ) and Novo Nordisk have recently partnered with AI companies to accelerate drug discovery. J&J aims to halve the time for generating new drug leads using AI, while Novo Nordisk is collaborating with OpenAI to analyze complex datasets and expedite medicine development.

Market impact: These partnerships are driving a shift in the pharmaceutical industry, with AI becoming a crucial tool for drug discovery. Companies like Simulations Plus (SLP) are also benefiting from increased demand for AI-enabled modeling in drug development. This could lead to faster drug approvals, increased pipelines, and potentially higher valuations for these companies.

What to watch next: Upcoming catalysts include J&J's and Novo Nordisk's quarterly earnings (Q2 2023, July 18 and August 2 respectively) to assess the initial progress of their AI initiatives. Additionally, monitor regulatory decisions on AI-driven drug candidates, such as those from the FDA, to gauge the regulatory environment for AI in drug discovery.